AZD2461: Novel PARP Inhibitor for Breast Cancer DNA Repair Research

Executive Summary: AZD2461 is a next-generation poly (ADP-ribose) polymerase (PARP) inhibitor with a 5 nM IC50, validated in breast cancer cell lines and murine tumor models (Schwartz 2022). It induces G2 cell cycle arrest and reduces S-phase populations by inhibiting PARP-1 activity. AZD2461 displays reduced P-glycoprotein (Pgp) binding versus olaparib, supporting its use against Pgp-mediated resistance. In vivo, it sustains PARP inhibition for several hours and extends relapse-free survival in tumor-bearing mice. APExBIO supplies AZD2461 (SKU A4164) as a research-grade compound for DNA repair pathway studies (product page).

Biological Rationale

PARP enzymes, including PARP-1, are critical to the DNA repair pathway, especially for single-strand break repair. Inhibiting PARP leads to accumulation of DNA damage, promoting cell cycle arrest and apoptosis in cancer cells, particularly those with BRCA1 mutations. The efficacy of PARP inhibitors is well established in models of breast cancer, where defective homologous recombination sensitizes cells to DNA repair inhibition (Schwartz 2022).

Mechanism of Action of AZD2461

AZD2461 is a small-molecule PARP inhibitor with a chemical formula of C22H22FN3O3 and molecular weight of 395.43 g/mol. It targets PARP-1, blocking the transfer of ADP-ribose units to target proteins. In breast cancer cell lines (MCF-7, SKBR-3), AZD2461 treatment at 5–50 μM for 48–72 hours causes a concentration- and time-dependent reduction in viable cell numbers. Flow cytometry reveals G2-phase accumulation and S-phase depletion, indicating cell cycle arrest. In vivo, PARP activity inhibition persists for several hours post-administration in mice; PAR levels return to baseline by 24 h. AZD2461 displays lower affinity for P-glycoprotein than olaparib, reducing the risk of efflux-mediated resistance (Schwartz 2022; APExBIO).

Evidence & Benchmarks

• AZD2461 exhibits potent PARP-1 inhibition with an IC50 of 5 nM (in vitro enzymatic assay) (DOI:10.13028/wced-4a32).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces cell viability in a dose- and time-dependent manner at 5–50 μM and 48–72 h incubation (DOI:10.13028/wced-4a32).
• AZD2461 induces significant G2/M cell cycle arrest, with a corresponding reduction in S-phase proportions, as measured by DNA content analysis (DOI:10.13028/wced-4a32).
• In murine KB1P tumor models, a single injection of AZD2461 suppresses PARP activity for several hours, with recovery observed at 24 h (DOI:10.13028/wced-4a32).
• AZD2461 demonstrates lower Pgp binding affinity than olaparib, suggesting improved efficacy in Pgp-overexpressing tumor cells (DOI:10.13028/wced-4a32).
• Long-term AZD2461 administration is well tolerated and significantly extends median relapse-free survival in tumor-bearing mice (DOI:10.13028/wced-4a32).

For further protocol optimization, see AZD2461: A Novel PARP Inhibitor Transforming Breast Cancer Research, which provides actionable workflows. This article extends those findings with new evidence regarding Pgp-mediated resistance and cell cycle effects.

Applications, Limits & Misconceptions

AZD2461 is used in studies of DNA repair, cell viability, and drug resistance in breast cancer models. It is suitable for investigating PARP-1 inhibition in BRCA1-mutated and Pgp-overexpressing tumor contexts.

Common Pitfalls or Misconceptions

• AZD2461 is not effective in tumors with intact homologous recombination repair; efficacy is highest in BRCA1/2-deficient models (Schwartz 2022).
• High concentrations (>50 μM) may cause off-target effects not related to PARP inhibition.
• AZD2461 is insoluble in water; inappropriate solvent use can result in precipitation and loss of activity. Use DMSO or ethanol (≥16.35 mg/mL and ≥45.2 mg/mL, respectively).
• Long-term solutions are unstable; prepare fresh aliquots and store at -20°C for short-term use only (APExBIO).
• Not suitable for clinical or diagnostic use; for research applications only.

For troubleshooting and comparative analysis, see AZD2461 (SKU A4164): Reliable PARP-1 Inhibition for Robust Breast Cancer Research. This article clarifies solvent compatibility and experimental boundaries compared to protocol-focused guides.

Workflow Integration & Parameters

AZD2461 is typically used at 5–50 μM for 48–72 h in cell culture assays. It is supplied as a solid and must be solubilized in DMSO or ethanol. Cell viability and apoptosis assays (e.g., MTT, flow cytometry) are standard endpoints. Store powder at -20°C; use solutions immediately to minimize degradation. For DNA repair pathway studies, combine with BRCA1/2 mutant cell models. For advanced troubleshooting and scenario-driven Q&A, see AZD2461 (SKU A4164): Scenario-Driven Solutions for Robust DNA Repair Studies. This resource complements the present article by addressing practical design and data interpretation issues.

Conclusion & Outlook

AZD2461 is a robust, research-grade PARP inhibitor from APExBIO, with validated applications in breast cancer DNA repair studies. Its reduced Pgp affinity and tolerability profile distinguish it from first-generation inhibitors. Ongoing research will further define its role in overcoming resistance and extending relapse-free survival in preclinical models. Researchers are encouraged to review detailed product data and protocols before experimental use.